---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 68 evidence topics quoted from 28 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found, and CG Oncology has announced no price. Its Form 10-K states that the “pricing of existing drugs may limit the amount we will be able to charge for our products”. Published U.S. economic evaluations in BCG-unresponsive high-risk NMIBC address the approved comparators. A Ferring-funded budget impact model of nadofaragene firadenovec estimated a budget impact of $0.0010 to $0.0084 per member per month over 3 years in a plan of one million members for CIS ± Ta/T1 disease, and $0.0064 to $0.0548 when papillary-only disease was included; the authors note that cretostimogene was “under investigation in ongoing trials for similar indications” and was not modeled. A 5-year Medicare Markov model found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy. A Johnson & Johnson-funded 15-month cost-per-responder model estimated that 43.5% of patients treated with TAR-200 achieved and sustained a complete response for at least 12 months, against 18.8% to 26.8% for pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept plus BCG without reinduction, and 10.1% for valrubicin. The 2020 ICER review estimated $151,000 per QALY gained for nadofaragene firadenovec and $114,000 for pembrolizumab against a hypothetical comparator with a 0% complete response rate, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec. Two other models found pembrolizumab not cost-effective at its price at the time, one estimating that a 5.4% price reduction would make it cost-effective, and a further analysis found nadofaragene firadenovec cost-effective against radical cystectomy at $10,014 per QALY at a willingness-to-pay threshold of $100,000. ImmunityBio reported preliminary results of a health economic analysis, based on complete response rates from an indirect treatment comparison, in which nogapendekin alfa inbakicept plus BCG had a lower cost per sustained complete responder than TAR-200.

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599); [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/); [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037); [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/); [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/); [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/); [D'Andrea et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39550339/); [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

<a id="topic-4.1-2"></a>

#### Budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec

No evidence found.

<a id="topic-4.1-3"></a>

#### Cretostimogene grenadenorepvec in published economic models of the indication

> “In recent years, the FDA has approved several new agents for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1, including pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln + BCG, and TAR-200, while additional therapies such as cretostimogene grenadenorepvec are under investigation in ongoing trials for similar indications as of the drafting of this manuscript.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.1-4"></a>

#### Company statements on pricing of cretostimogene grenadenorepvec

> “Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-4.1-5"></a>

#### Budget impact of nadofaragene firadenovec in a United States health plan

> “To estimate the budget impact of adopting nadofaragene firadenovec for the treatment of adults with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors (CIS ± Ta/T1) from a US third-party payer’s perspective.”
> “In the base-case, the estimated per-member-per-month (PMPM) budget impact of adopting nadofaragene firadenovec ranged from $0.0010 in Year 1 to $0.0084 in Year 3.”
> “Funding for this study was provided by Ferring Pharmaceuticals.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.1-6"></a>

#### Cost-effectiveness of radical cystectomy and bladder-sparing treatments for BCG-unresponsive carcinoma in situ

> “We developed a Markov decision analytic model to assess five treatments: RC, nadofaragene, nogapendekin, pembrolizumab, and gemcitabine/docetaxel.”
> “For index patient 1, who is willing to try one line of therapy or proceed directly to RC, gemcitabine/docetaxel was the most cost-effective option. For index patient 2, open to two lines of therapy or upfront RC, RC was the most cost-effective. For index patient 3, willing to try up to 2 lines of FDA-approved therapy (pembrolizumab, nadofaragene, or nogapendekin) before RC, pembrolizumab was the most cost-effective option.”
> “Current pricing of bladder-sparing treatments poses significant financial barriers, highlighting the need for better treatment selection tools and more equitable pricing.”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.1-7"></a>

#### Cost per responder of TAR-200 versus FDA-approved comparators

> “A 15-month cost-per-responder model was developed from a Medicare payer perspective (2025 USD).”
> “At 15 months, the proportion of patients achieving and sustaining CR for ≥12 months was 43.5% for TAR-200, 18.8% for pembrolizumab, 21.9% for NF, 26.8% for NAI+BCG (36.6% with reinduction), and 10.1% for valrubicin.”
> “This study was funded by Johnson & Johnson.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.1-8"></a>

#### ICER review of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab

> “The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive NMIBC.”
> “The base-case cost-effectiveness, with each drug compared with the hypothetical comparator with a 0% CR at 3 months, were $151,000 per QALY gained for nadofaragene firadenovec, $382,000 per QALY gained for oportuzumab monatox, and $114,000 per QALY gained for pembrolizumab.”
> “The HBPB for nadofaragene firadenovec ranged from $158,600 to $262,000 per year.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

> “January 15, 2021 Update: A data entry error affected model results regarding nadofaragene firadenovec when used in the Ta/T1 population. Results have been corrected in this update, and include a revised Health-Benefit Price Benchmark (HBPB) range for nadofaragene firadenovec.”
> “As such, this ICER report should be considered no longer current with respect to oportuzumab monatox.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.1-9"></a>

#### Cost-effectiveness of nadofaragene firadenovec and pembrolizumab versus a hypothetical alternative

> “Nadofaragene firadenovec, at a placeholder price 10% higher than the price of pembrolizumab, had an incremental cost-effectiveness ratio of $263 000 and $145 000 per QALY gained in CIS and non-CIS populations, respectively. Pembrolizumab had an incremental cost-effectiveness ratio of $168 000 per QALY gained for CIS.”
> “The cost-effectiveness of nadofaragene firadenovec will depend upon its price.”

Source: [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)

<a id="topic-4.1-10"></a>

#### Cost-effectiveness of pembrolizumab versus salvage intravesical chemotherapy and radical cystectomy

> “At its current price, pembrolizumab is not cost-effective for bacillus Calmette-Guérin-unresponsive carcinoma in situ relative to radical cystectomy or salvage intravesical chemotherapy.”

Source: [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/)

<a id="topic-4.1-11"></a>

#### Cost-effectiveness of approved bladder-sparing agents in a systematic review and Markov model

> “Compared with using radical cystectomy to treat patients failing BCG therapy, at a willingness-to-pay threshold of 100 000 USD, nadofaragene firadenovec was cost effective, with an incremental cost-effectiveness ratio (ICER) of 10 014 USD per quality-adjusted life year (QALY), while nogapendekin alfa inbakicept was less cost effective than nadofaragene firadenovec (ICER of 44 602 USD per QALY). Pembrolizumab, which dominated, was both less costly and more effective than the other strategies.”

Source: [D'Andrea et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39550339/)

<a id="topic-4.1-12"></a>

#### Cost-effectiveness of salvage treatments in a German payer setting

> “Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.”

Source: [Rieger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38491799/)

<a id="topic-4.1-13"></a>

#### Manufacturer-reported cost-consequence analysis of nogapendekin alfa inbakicept plus BCG versus TAR-200

> “ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced preliminary results from a new health economic analysis demonstrating that ANKTIVA® (nogapendekin alfa inbakicept-pmln; NAI) plus Bacillus Calmette–Guérin (BCG) achieved a lower cost per sustained complete responder compared to TAR-200 in patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ ± papillary disease (NMIBC CIS).”

Source: [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

<a id="topic-4.2.1-1"></a>

##### Budget impact model of cretostimogene grenadenorepvec: approach and framework

No evidence found.

<a id="topic-4.2.1-2"></a>

##### Good-practice framework for budget impact analysis

> “The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.”
> “Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.”
> “The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.1-3"></a>

##### Structure of a published budget impact model of nadofaragene firadenovec

> “The budget impact was estimated as the differences in total healthcare costs between the following two scenarios: 1) with nadofaragene firadenovec market entry (i.e. a market basket of nadofaragene firadenovec and existing treatment regimens) and 2) without nadofaragene firadenovec market entry (i.e. a market basket of existing treatment regimens only).”
> “Existing treatment regimens for high-risk BCG-unresponsive NMIBC included intravesical treatments – valrubicin, mitomycin C, gemcitabine, BCG + interferon-alpha, and gemcitabine/docetaxel – and systemic therapy with intravenous pembrolizumab.”
> “The total healthcare costs consisted of the following components: drug and drug administration costs, surveillance and disease management costs (including disease-free surveillance costs, recurrence costs, and progression costs), cystectomy costs, and treatment-related adverse events (AE) costs.”
> “Nogapendekin alfa inbakicept-pmln and TAR-200 were not included in the model due to their recent FDA approval and the lack of mature, publicly available market share data.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.1-4"></a>

##### Potential budget impact method of the ICER review

> “Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events.”
> “For 2019-2020, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately $819 million per year for new drugs.”
> “In this analysis, we assumed that patients eligible for nadofaragene firadenovec or oportuzumab monatox would otherwise have been treated with “usual care” as typified by the hypothetical treatment used in the base case (i.e., no specific bladder cancer-related treatment).”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.1-5"></a>

##### Model structures of published cost-effectiveness and cost-per-responder analyses

> “A Markov decision analytic model was created using TreeAge Pro software (TreeAge Software, Inc, Williamstown, Massachusetts).”
> “Each treatment option modelled as a Markov node with health states including surveillance, treatment toxicity, recurrence, progression to MIBC, metastasis, and death (Figure 1).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “After treatment initiation with TAR-200 or one of 4 FDA-approved comparator treatments, patients could either 1) attain and sustain CR or 2) not respond; attainment of CR was based on the overall CR rate, and transitions from a state of CR to a state of non-response were evaluated monthly (starting at month 4 for up to 15 months) based on DOR data.”
> “Once in a state of non-response, patients either underwent an RC or received subsequent treatment.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

> “We developed a de novo semi-Markov decision analytic model with model structure and inputs informed by key clinical trials, previous economic models, systematic literature reviews, and input from stakeholders (patients, advocacy groups, clinicians, payers, researchers, and manufacturers).”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

<a id="topic-4.2.2-1"></a>

##### Budget impact model of cretostimogene grenadenorepvec: perspective and time frame

No evidence found.

<a id="topic-4.2.2-2"></a>

##### Perspective recommended for budget impact analysis

> “The Task Force recommends that the budget impact of a new health technology should consider the perspective of the specific health-care decision-maker.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

> “In either case, the BIA should use data that reflect values specific to a particular decision maker's population.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

<a id="topic-4.2.2-3"></a>

##### Perspective and time horizon of a published budget impact model of nadofaragene firadenovec

> “The analysis was conducted from the perspective of a US third-party payer, simulating a hypothetical healthcare plan with one million covered lives over a 3-year horizon following the market entry of nadofaragene firadenovec”
> “All costs were estimated in 2024 US dollars (USD)”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.2-4"></a>

##### Perspective and time horizon of the ICER review

> “All costs were undiscounted and estimated over a five-year time horizon, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with the new therapy.”
> “The base case used a US health care sector perspective.”
> “The decision model was evaluated over a lifetime time horizon with three-month cycles.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.2-5"></a>

##### Perspectives and time horizons of other published analyses

> “Cost-effectiveness was evaluated over a 5-year period using a willingness-to-pay threshold of $100,000 per quality-adjusted life-year from the US Medicare perspective.”
> “Cycle length was set at 3 months with the model terminating after 20 cycles, representing a 5-year time horizon.”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “Costs were evaluated over a 15-month time horizon, which was selected to account for the timing of initial response assessment at 3 months and the 12-month DOR.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

> “We developed a Markov cohort simulation model with a 3-month cycle length and lifetime horizon to estimate the total costs, QALYs, and cost per additional QALY from the health sector perspective.”

Source: [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

##### Budget impact model of cretostimogene grenadenorepvec: eligible population inputs

No evidence found.

<a id="topic-4.2.3-2"></a>

##### Company estimate of the addressable BCG-unresponsive population

> “Based on internal research derived from the National Cancer Institute Surveillance, Epidemiology, and End Results Program’s (NIH SEER) database, secondary claims data analytics and management assumptions, the BCG-unresponsive NMIBC segment may represent up to 25,000 addressable patients.”
> “Cretostimogene is currently in clinical development for the treatment of patients with high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), which potentially represents up to 150,000 addressable patients in the United States.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-4.2.3-3"></a>

##### Planned inclusion of papillary-only disease in the marketing application

> “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-4.2.3-4"></a>

##### Bladder cancer incidence and prevalence in the United States

| Measure | Value |
| --- | --- |
| Estimated new cases in 2026 | “84,530” |
| Estimated deaths in 2026 | “17,870” |

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

> “The rate of new cases of bladder cancer was 17.9 per 100,000 men and women per year.”
> “In 2023, there were an estimated 763,031 people living with bladder cancer in the United States.”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-4.2.3-5"></a>

##### Eligible population inputs in a published budget impact model

> “In the base-case analysis, the model considered adults (aged ≥18 years) with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1. Prevalent cases were considered in Year 1 and incident cases were considered in Years 2–3.”
> “Specifically, the prevalence of bladder cancer was 0.0634% and the incidence was 0.0244%, based on US Surveillance, Epidemiology, and End Results Program (SEER) registry data”
> “a real-world study of treatment patterns and clinical outcomes of US patients with bladder cancer based on the SEER-Medicare claims data, 73.1% of all patients with bladder cancer had NMIBC and, among them, 42.3% were classified as high-risk; 16.5% of patients with high-risk NMIBC had CIS ± Ta/T1 while 83.5% had high-grade Ta/T1 only”
> “Among patients with high-risk NMIBC, 56.5% were treated with BCG”
> “and 30% of those were unresponsive to BCG”
> “Among adults with high-risk, BCG-unresponsive NMIBC, 92.6% and 81.2% remained alive at Years 2 and 3, respectively, based on an analysis of SEER Medicare claims data”
> “An annual recurrence rate of 55.1% was used”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.3-6"></a>

##### Eligible patients per one million health plan members

> “In a hypothetical health plan with one million lives, the number of adults with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1 who were eligible for nadofaragene firadenovec was estimated to be 5.5 in Year 1, 4.9 in Year 2, and 4.5 in Year 3 (Table 1).”
> “In Scenario analysis 1, which considered incident bladder cancer cases only, the size of the target population was estimated to be 2.1 patients in each year.”
> “In Scenario analysis 2, when considering the broader population eligible for nadofaragene firadenovec to the pooled population of CIS ± Ta/T1 plus Ta/T1 only, the size of the target population was estimated to be 33.2 patients in Year 1, 29.7 in Year 2, and 27.5 in Year 3.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.3-7"></a>

##### Projected market shares in a published budget impact model

> “Market shares of nadofaragene firadenovec were projected to be 2% in Year 1, 6% in Year 2, and 18% in Year 3, according to market research by Ferring Pharmaceuticals (data on file).”
> “Specifically, the market share of gemcitabine/docetaxel in Year 1 was based on Yang et al. (2024) (7.1%)”
> “In the absence of nadofaragene firadenovec market entry, the market shares of existing treatments were proportionally scaled to sum to 100% while maintaining their relative distribution.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.3-8"></a>

##### Eligible prevalent population and uptake in the ICER review

> “The National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER) estimates that prevalence of bladder cancer was 712,614 people in the US in 2017.”
> “Kirkali et al. estimated that approximately 70% of bladder cancers present as NMIBC, with approximately 70% classified as Ta, 20% as T1, and 10% as CIS.”
> “We assumed that T1 and CIS are considered high-grade disease while 10% of Ta cancers are considered high grade.”
> “the proportion of patients who are BCG-unresponsive/refractory, we assumed that approximately 38% will be classified as BCG non-responders.”
> “Applying these proportions to the estimated prevalent NMIBC population (712,614), we arrived at an estimate of 70,135 individuals as the eligible population for these treatments, with 73% (51,180) being Ta and T1 patients and 27% (18,956) being CIS patients.”
> “Among these eligible patients, we assumed a 20% uptake each year over five years, or 14,027 patients per year.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.3-9"></a>

##### Proportion of patients unresponsive to BCG

> “However, more than 40% of patients with high-risk NMIBC do not respond to initial BCG treatment, and many experience loss of response over time”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “Despite treatment with intravesical Bacillus Calmette-Guérin (BCG) therapy, more than half of patients with NMIBC develop recurrence or progression within 1–2 years and up to 40% eventually become unresponsive to BCG”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.3-10"></a>

##### Proportion of patients who decline or are ineligible for radical cystectomy

> “up to 80% of patients decline or are ineligible for the procedure due to associated morbidity, mortality, or quality of life concerns”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

##### Budget impact model of cretostimogene grenadenorepvec: cost assumptions

No evidence found.

<a id="topic-4.2.4-2"></a>

##### Cretostimogene grenadenorepvec price

No evidence found.

<a id="topic-4.2.4-3"></a>

##### Cretostimogene grenadenorepvec dosing schedule in BOND-003

> “The initial induction course of therapy is six weekly doses of cretostimogene”
> “Patients who achieve a CR at month three receive maintenance treatments, involving three weekly cretostimogene doses administered at the same concentration every three months for the first 12 months and every six months for the next 24 months.”
> “Patients who do not achieve a CR after the first induction course may receive a second induction course of six weekly cretostimogene treatments at month 3, rather than the maintenance course involving three weekly treatments.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-4.2.4-4"></a>

##### Nadofaragene firadenovec wholesale acquisition cost

| Field | Value |
| --- | --- |
| NDC | “55566-1050-01” |
| Dosage form | “box” |
| Pack size | “4 vials x 20 ml” |
| WAC | “$62,740.70” |

Source: [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet)

> “This above pricing information is being provided pursuant to Connecticut House Bill Substitute No. 6669 and is accurate as of October 2, 2026.”

Source: [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet)

<a id="topic-4.2.4-5"></a>

##### Nadofaragene firadenovec dosing

> “instilled once every three (3) months into the bladder via a urinary catheter”
> “If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-4.2.4-6"></a>

##### Nogapendekin alfa inbakicept wholesale acquisition cost

| Field | Value |
| --- | --- |
| Marketed product | “ANKTIVA 400 mcg/0.4 mL” |
| NDC | “81481-803-01” |
| WAC price (400 mcg/0.4 mL vial) | “$35,800.00” |

Source: [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf)

> “WAC does not reflect discounts, rebates and other reductions in price.”
> “Data as of: January 1, 2025”

Source: [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf)

<a id="topic-4.2.4-7"></a>

##### Nogapendekin alfa inbakicept dosing

> “For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks.”
> “For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses).”
> “For patients with no evidence of high-grade disease at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-4.2.4-8"></a>

##### Pembrolizumab list price

> “for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.”
> “The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88.”
> “The list price is also referred to as wholesale acquisition cost or WAC.”
> “The list price does not include other treatment-related costs. The list price is current as of September 2026.”

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)

<a id="topic-4.2.4-9"></a>

##### Pembrolizumab dosing in BCG-unresponsive NMIBC

> “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months”
> “Patients received KEYTRUDA 200 mg every 3 weeks until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or progressive disease.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-4.2.4-10"></a>

##### Gemcitabine intravesical system wholesale acquisition cost

No evidence found.

<a id="topic-4.2.4-11"></a>

##### Gemcitabine intravesical system dosing

> “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks for up to 6 months (8 doses), followed by once every 12 weeks for up to 18 months (6 doses), or until persistent or recurrent NMIBC, disease progression, or unacceptable toxicity.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-4.2.4-12"></a>

##### Medicare Part B payment limits for comparator agents, fourth quarter of 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
| --- | --- | --- | --- | --- |
| J9029 nadofaragene firadenovec (Adstiladrin) | “Instill adstiladrin, tx dose” | “PER THERAPEUTIC DOSE” | “65200.563” | “20.000” |
| J9028 nogapendekin alfa inbakicept (Anktiva) | “Inj, nogapendekin pmln, 1mcg” | “1 MCG” | “94.139” | “20.000” |
| J9183 gemcitabine intravesical system (Inlexzo) | “Gemcitabine intravesical sys” | “225 MG” | “73054.053” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J9030 BCG live intravesical | “Bcg live intravesical 1mg” | “1 MG” | “3.532” | “20.000” |
| J9357 valrubicin | “Valrubicin injection” | “200 MG” | “1230.664” | “20.000” |
| J9201 gemcitabine | “In gemcitabine hcl nos 200mg” | “200 MG” | “2.734” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| J9280 mitomycin | “Mitomycin injection” | “5 MG” | “34.838” | “20.000” |

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-13"></a>

##### Medicare physician fee schedule relative value units for office-based instillation, surveillance, and evaluation services, 2026

> “2026 National Physician Fee Schedule Relative Value File October Release”
> “RELEASED 08/26/2026”

Source: [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)

| CPT code | Description | Non-facility total RVU | Facility total RVU | Conversion factor |
| --- | --- | --- | --- | --- |
| 51720 | “Treatment of bladder lesion” | “2.75” | “1.14” | “33.4009” |
| 51701 | “Insert bladder catheter” | “1.36” | “0.66” | “33.4009” |
| 52000 | “Cystourethroscopy” | “6.46” | “2.13” | “33.4009” |
| 52204 | “Cystoscopy w/biopsy(s)” | “10.64” | “3.80” | “33.4009” |
| 88112 | “Cytopath cell enhance tech” | “1.96” | “1.96” | “33.4009” |
| 88120 | “Cytp urne 3-5 probes ea spec” | “16.23” | “16.23” | “33.4009” |
| 74178 | “Ct abd&plv wo cntr flwd cntr” | “10.12” | “10.12” | “33.4009” |
| 99214 | “Office o/p est mod 30 min” | “4.06” | “2.53” | “33.4009” |

Source: [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)

<a id="topic-4.2.4-14"></a>

##### Medicare physician fee schedule relative value units for transurethral resection and radical cystectomy, 2026

| CPT code | Description | Facility total RVU | Global days | Conversion factor |
| --- | --- | --- | --- | --- |
| 52234 | “Cystoscopy and treatment” | “6.49” | “000” | “33.4009” |
| 52235 | “Cystoscopy and treatment” | “7.62” | “000” | “33.4009” |
| 52240 | “Cystoscopy and treatment” | “10.31” | “000” | “33.4009” |
| 51570 | “Removal of bladder” | “39.05” | “090” | “33.4009” |
| 51575 | “Removal of bladder & nodes” | “48.18” | “090” | “33.4009” |
| 51590 | “Remove bladder/revise tract” | “51.25” | “090” | “33.4009” |
| 51595 | “Remove bladder/revise tract” | “57.93” | “090” | “33.4009” |
| 51596 | “Remove bladder/create pouch” | “62.52” | “090” | “33.4009” |

Source: [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip)

<a id="topic-4.2.4-15"></a>

##### Unit cost inputs in a published budget impact model

> “The unit cost for nadofaragene firadenovec was $60,000.00 per instillation based on the average wholesale acquisition cost from Truven Redbook Online database (now Merative Micromedex Redbook Online)”
> “with an administration cost per instillation of $42.90 based on the Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule”
> “The monthly recurrence cost of $2,723.10 was obtained from Yang et al. (2021)”
> “The monthly progression cost of $6,004.60 was also obtained from Yang et al. (2021)”
> “The unit cost associated with cystectomy, including the cystectomy procedure cost and 90-day direct hospital costs, was estimated to be $46,646 based on Leow et al.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.4-16"></a>

##### Three-month Medicare costs in a published cost-effectiveness model, 2024

| Item | 3 month cost (USD) | Range |
| --- | --- | --- |
| Radical cystectomy without complications | “15850” | “14439–16472” |
| Radical cystectomy with major complications | “37330” | “36275–37952” |
| Pembrolizumab, 200 mg every 3 weeks | “46356” | “0–250,000” |
| Gemcitabine-docetaxel induction | “828” | “0–250,000” |
| Gemcitabine-docetaxel maintenance | “414” | “0–250,000” |
| Nadofaragene, 75 mL every 3 months | “63594” | “0–250,000” |
| Nogapendekin alfa inbakicept-BCG induction | “216189” | “0–250,000” |
| Nogapendekin alfa inbakicept-BCG maintenance | “108095” | “0–250,000” |
| Recurrence, initial cost (TURBT, office visit) | “3779” | “2070–5539” |
| Surveillance on bladder-sparing therapy | “3638 per year” | “3384–7284” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “We calculated 2024 U.S. healthcare costs from a Medicare payer perspective. Costs were obtained for drugs, procedures, tests, and hospital admissions through Medicare payment schedules for CPT, DRG, and HCPCS codes (Table 2).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.2.4-17"></a>

##### Treatment cost sources in a published cost-per-responder model

> “Initial and subsequent treatment costs were derived from the average sales price (ASP) pricing file with TAR-200 pricing based on the IBM Micromedex RED BOOK wholesale acquisition cost, as ASP pricing was not yet available at the time of this study; generic costs were selected for valrubicin”
> “Over the 15-month model time horizon, excluding NAI+BCG reinduction, the total cost per patient treated with TAR-200 was $823,824, compared with $485,781 for pembrolizumab, $504,487 for NF, $731,075 for NAI+BCG, and $347,861 for valrubicin.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.4-18"></a>

##### Placeholder drug prices in the ICER review

> “Since the prices for nadofaragene firadenovec and oportuzumab monatox were not available at the time of the report, the price for nadofaragene firadenovec was set to equal the annual price of pembrolizumab ($164,337), whereas oportuzumab was set at $150,000 per year net of all rebates based on analyst estimates.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.4-19"></a>

##### Costs of care after BCG with and without progression

> “Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].”
> “Annualized HRU and mean medical costs (2020 United States dollars) were estimated and compared between patients with versus without progression.”

Source: [Yang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33543424/)

<a id="topic-4.2.4-20"></a>

##### Costs of radical cystectomy in United States claims data

> “Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index.”

Source: [Williams et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40122296/)

<a id="topic-4.2.4-21"></a>

##### Five-year surveillance costs by NMIBC risk group

> “Cumulative costs of care over a 5-year period were $52,125 for low-risk, $146,250 for intermediate-risk, and $366,143 for high-risk NMIBC.”

Source: [Mossanen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30446799/)

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

<a id="topic-4.2.5-1"></a>

##### Budget impact model of cretostimogene grenadenorepvec: model outcomes

No evidence found.

<a id="topic-4.2.5-2"></a>

##### Outcomes recommended for budget impact analysis

> “The outcomes of the BIA should be presented in the format of interest to health care decision makers.”
> “In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.5-3"></a>

##### Outcomes reported by published economic analyses in the indication

> “Model outputs included estimates of budget and budget impact in each year over the 3-year period, both on a total plan and a per member per month (PMPM) basis.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “The primary outcome was 5-year cost-effectiveness, measured by incremental cost-effectiveness ratio (ICER, calculated as incremental cost divided by incremental effectiveness) and net monetary benefit (NMB, calculated as willingness to pay [WTP] X effectiveness - cost).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “The total cost per treated patient and total cost per responder, defined as achieving and sustaining CR for ≥12 months was reported at 15 months.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

> “For each population, we estimated time in progression-free state, total costs, total quality-adjusted life-years (QALYs), total equal value life-years gained (evLYGs), and total life-years (LYs) for each treatment over a lifetime time horizon.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.5-4"></a>

##### Health-state utility values used in a published cost-effectiveness model

| Health state | Utility value | Range | Toll |
| --- | --- | --- | --- |
| Bladder cancer | “0.95” | “0.93–0.97” | “Lifetime” |
| RC/IC (radical cystectomy with ileal conduit) | “0.8” | “0.7–0.9” | “3 months” |
| Post-cystectomy state | “0.9” | “0.8–0.95” | “Lifetime” |
| Metastatic disease | “0.62” | “0.5–0.7” | “Lifetime” |
| Recurrence | “0.8” | “0.75–0.95” | “3 months” |
| Acute minor toxicity (urinary tract infection), disutility | “−0.15” | “0–0.3” | “2 weeks” |
| Acute major toxicity (hospitalization), disutility | “−0.2” | “0–0.3” | “1 month” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

<a id="topic-4.2.6.1-1"></a>

###### Budget impact model of cretostimogene grenadenorepvec: base-case results

No evidence found.

<a id="topic-4.2.6.1-2"></a>

###### Base-case budget impact of nadofaragene firadenovec in a plan of one million members

> “On a plan total basis, the budget during Years 1, 2, and 3 were $358,037, $487,675, and $564,877, respectively, under the scenario without nadofaragene firadenovec entry versus $369,997, $523,127, and $665,977 under the scenario with nadofaragene firadenovec entry, corresponding to a budget impact of $11,960, $35,452, and $101,099”
> “On a per-member-per-month (PMPM) basis, the budgets from Years 1 − 3 were $0.0298, $0.0406, and $0.0471, respectively, under the scenario without nadofaragene firadenovec entry versus $0.0308, $0.0436, and $0.0555 under the scenario with nadofaragene firadenovec entry, corresponding to a budget impact of $0.0010, $0.0030, and $0.0084 PMPM”
> “Increased drug and administration costs were partially offset by cost savings from reduced disease progression, fewer cystectomies, and lower AE rates.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.6.1-3"></a>

###### Potential budget impact of nadofaragene firadenovec in the ICER review

> “The average potential budgetary impact for nadofaragene firadenovec was an additional per-patient cost of approximately $128,000 in year one, with net annual savings in following years leading to cumulative costs per patient of approximately $98,000 by year five.”
> “As shown in Figure 8.2, approximately 52% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of $819 million at the assumed placeholder price.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.6.1-4"></a>

###### Base-case cost-effectiveness of radical cystectomy and bladder-sparing treatments over 5 years

| Index patient and strategy | Cost (5-year USD) | Effectiveness (5-year QALY) | ICER (USD/QALY) | Net monetary benefit |
| --- | --- | --- | --- | --- |
| Index patient 1: gemcitabine/docetaxel | “78,539” | “3.95” | “Ref.” | “316,053” |
| Index patient 1: radical cystectomy | “96,909” | “3.78” | “−109.912” | “280,971” |
| Index patient 1: pembrolizumab | “226,879” | “3.82” | “−1,137,869” | “154,677” |
| Index patient 1: nadofaragene | “296,318” | “3.84” | “−2,154,264” | “88,165” |
| Index patient 1: NAI-BCG | “529,801” | “3.85” | “−4,685,203” | “−144,840” |
| Index patient 3: pembrolizumab | “419,022” | “3.88” | “Ref.” | “−31,083” |
| Index patient 3: nadofaragene | “449,307” | “3.90” | “1,469,775” | “−59,307” |
| Index patient 3: NAI-BCG | “704,172” | “3.83” | “−3,847,835” | “−320.796” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.2.6.1-5"></a>

###### Base-case cost per responder of TAR-200 versus FDA-approved comparators

> “The TAR-200 cohort demonstrated the lowest total cost per patient achieving and sustaining CR for ≥12 months, with an estimated cost of $1,892,569 when NAI+BCG reinduction was not considered.”
> “In comparison with the other treatment cohorts, TAR-200 was associated with meaningful cost savings per patient achieving and sustaining CR for ≥12 months, including $698,262 relative to pembrolizumab, $406,840 relative to NF, $832,346 relative to NAI+BCG, and $1,541,999 relative to valrubicin.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.6.1-6"></a>

###### Base-case incremental cost-effectiveness ratios in the ICER review, CIS ± Ta/T1

| Intervention | Cost per QALY gained | Cost per evLYG | Cost per year in progression-free state |
| --- | --- | --- | --- |
| Nadofaragene firadenovec | “$151,000” | “$135,000” | “$100,000” |
| Oportuzumab monatox | “$382,000” | “$343,000” | “$281,000” |
| Pembrolizumab | “$114,000” | “$103,000” | “$76,000” |

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.6.1-7"></a>

###### Manufacturer-reported cost-consequence results for nogapendekin alfa inbakicept plus BCG versus TAR-200

> “Cost per cystectomy avoided: ANKTIVA plus BCG demonstrated savings of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200”
> “Cost per complete responder: Savings of $313,775 at Year 1 and $282,013 at Year 2”
> “Cost reductions were primarily driven by lower drug acquisition and administration costs, based on complete response rates derived from an indirect treatment comparison”
> “49.6% for ANKTIVA plus BCG versus 45.9% for TAR-200.”

Source: [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

<a id="topic-4.2.6.2-1"></a>

###### Budget impact model of cretostimogene grenadenorepvec: scenario analyses

No evidence found.

<a id="topic-4.2.6.2-2"></a>

###### Scenario and sensitivity analyses recommended for budget impact analysis

> “Sensitivity analysis should be of alternative scenarios chosen from the perspective of the decision maker.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “The Task Force recommends that budget impact analyses be generated as a series of scenario analyses in the same manner that sensitivity analyses would be provided for CEAs.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.6.2-3"></a>

###### Scenario and sensitivity analyses of a published budget impact model

> “Scenario analyses demonstrated that even examining a broader population including papillary disease-only patients, the budget impact remained modest ($0.0064-$0.0548 PMPM from Years 1–3). Sensitivity analyses confirmed that results were most influenced by uptake rate, drug cost, and target population size.”
> “Due to the smaller size of the target population, the Year 3 budget impact on a PMPM basis was $0.0039, lower than the base-case results.”
> “In Scenario analysis 3, the budget impact was similar to that of the base-case ($0.0080 PMPM in Year 3).”
> “Overall, the results from the DSAs were similar to the base-case analysis and, in Year 3, the budget impact of nadofaragene firadenovec entry ranged from $0.0069 to $0.0100 PMPM.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.6.2-4"></a>

###### Sensitivity analyses of a published cost-effectiveness model

> “Gemcitabine/docetaxel lost cost effectiveness compared to RC if the one-year recurrence free survival decreased from 60% to 50.4%, if the one-year progression free survival decreased from 97% to 92.2%, if the upstaging rate with delayed RC was greater than or equal to 36%, or if the three-month gemcitabine/docetaxel costs exceeded $8,808.”
> “One-way sensitivity analysis showed the model was sensitive to cost alone. Nadofaragene became cost effective with a 21% reduction in 3-month cost, while NAI-BCG would require a 67% cost reduction.”
> “In a probabilistic sensitivity analysis with all model parameters varied simultaneously, the most cost-effective strategy remained pembrolizumab (54%), followed by nadofaragene (35%), and NAI-BCG (11%).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.2.6.2-5"></a>

###### Scenario and sensitivity analyses of a published cost-per-responder model

> “TAR-200 continued to demonstrate the lowest total cost per patient achieving and sustaining CR for ≥12 months when reinduction with NAI+BCG was incorporated into the analysis, with an estimated cost of $1,897,937.”
> “The probabilistic sensitivity analysis found a cost-per-responder advantage for TAR-200 relative to other FDA-approved treatments across 58-97% of input specifications, depending on the comparator (Figure 5a through Figure 5e).”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.6.2-6"></a>

###### Scenario analyses in the ICER review

> “In scenario analyses, when the CR of the hypothetical comparator was increased to 20% in the CIS ± Ta/T1 population, the incremental cost-effectiveness ratio for nadofaragene firadenovec and oportuzumab monatox increased to $155,000 and $407,000, respectively.”
> “The model’s base-case assumption of an ineffective (0% CR) hypothetical comparator is likely overly conservative, so the base-case results can be viewed as the most optimistic scenario and should therefore be interpreted with caution.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.6.2-7"></a>

###### Price reductions required for cost-effectiveness of pembrolizumab

> “A 5.4% reduction in pembrolizumab's price would make it cost-effective.”

Source: [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)

> “For index patient 2, pembrolizumab required >90% price reduction to be cost-effective (incremental cost-effectiveness ratios $1,073,240/quality-adjusted life year).”

Source: [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/)

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary

Task force good-practice guidance lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker and presentation as a series of scenario analyses. For cretostimogene grenadenorepvec, two of these inputs are not yet available: a price, and a labeled population and dosing schedule. CG Oncology expects to complete its BLA “before the end of March 2027” and, after FDA feedback, plans to include high-grade papillary-only disease alongside CIS with or without papillary tumors.

The eligible population depends on which BCG-unresponsive disease is included. CG Oncology estimates up to 25,000 addressable patients with BCG-unresponsive NMIBC from internal research. In the nadofaragene firadenovec budget impact model of one million members, 5.5 adults with CIS ± Ta/T1 disease were eligible in Year 1, against 33.2 when papillary-only disease was added; that model applied 56.5% BCG treatment and 30% BCG unresponsiveness. The 2020 ICER review assumed 38% BCG non-response and derived 70,135 prevalent eligible individuals, of whom 18,956 (27%) had CIS. The authors of that model state that up to 80% of patients decline or are ineligible for cystectomy.

On costs, the Form 10-K describes cretostimogene as a six-week induction course, with three weekly maintenance doses every three months for the first 12 months and every six months for the next 24 months. Comparator list prices are $62,740.70 per Adstiladrin box (“4 vials x 20 ml”; instilled once every three months; October 2026), $35,800.00 per 400 mcg Anktiva vial (January 2025), and $25,034.88 per pembrolizumab dose given every 6 weeks (September 2026); no wholesale acquisition cost was found for the gemcitabine intravesical system, whose fourth-quarter 2026 Medicare Part B payment limit is $73,054.053 per 225 mg system. Each intravesical instillation also carries administration and surveillance costs (CPT 51720, 52000, 88112), and in the nadofaragene firadenovec model increased drug and administration costs were partially offset by savings from reduced progression, fewer cystectomies, and lower adverse event rates. In the published models, results were most influenced by uptake rate, drug cost, and target population size in the budget impact model, and the 5-year Markov model was sensitive to cost alone in one-way sensitivity analysis. The budget impact model and the cost-per-responder model were funded by Ferring Pharmaceuticals and Johnson & Johnson, and the nogapendekin alfa inbakicept analysis is a preliminary report from ImmunityBio.

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/); [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/); [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates); [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599); [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf); [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet); [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download); [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf); [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/); [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip); [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/); [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037); [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

<a id="topic-4.2.7-2"></a>

##### Company statements on coverage and reimbursement of cretostimogene grenadenorepvec

> “For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs.”
> “Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.”
> “It is possible that a third-party payor may consider our products as substitutable and offer to reimburse patients only for the less expensive product.”
> “In particular, given a significant portion of large urology practices are concentrated in a relatively small number of urology physician groups, market adoption by such groups will be an important factor in potential commercial success.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-4.2.7-3"></a>

##### Expected completion of the marketing application

> “To incorporate the additional data, we now expect to complete the submission before the end of March 2027.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-4.2.7-4"></a>

##### Limitations stated by the authors of a published budget impact model

> “Key limitations include reliance on projected market shares for nadofaragene firadenovec, omission of recently approved treatments (nogapendekin alfa inbakicept-pmln and TAR-200) due to the lack of publicly available market share data, and assumptions to derive clinical outcomes for certain treatments due to lack of reported data.”
> “The market share estimate for nadofaragene firadenovec is based on sponsor-conducted research and should be interpreted as exploratory rather than predictive.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.7-5"></a>

##### Pricing and coverage recommendations of the ICER review

> “Manufacturers should set prices based on the added clinical value of treatments over lower-cost regimens. Leapfrogging these lower-cost regimens and setting prices relative to higher-cost options adds to the growing financial toxicity of oncology care.”
> “It seems likely that the FDA label for the emerging treatments will be limited to BCG-unresponsive patients, and payers may therefore wish to consider requiring documentation of a trial of BCG as a criterion for coverage.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.7-6"></a>

##### Data sources recommended for budget impact inputs

> “Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
